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Abstract
Background: Human induced pluripotent stem cells (iPSCs) possess remarkable
self-renewal capacity and the potential to differentiate into novel cell types, such
as mesenchymal stem cells (MSCs). iPSC-MSCs have been shown to enhance tis-
sue regeneration and attenuate tissue ischaemia; however, their contribution to
the immune regulation of Th2-skewed allergic rhinitis (AR) and asthma remains
unclear.
Objective: This study compared the immunomodulatory effects of iPSC-MSCs
and bone marrow-derived MSCs (BM-MSCs) on lymphocyte proliferation, T-cell
phenotypes and cytokine production in peripheral blood mononuclear cells
(PBMCs) in patients with AR, and investigated the possible molecular mecha-
nisms underlying the immunomodulatory properties of iPSC-MSCs.
Methods: In co-cultures of PBMCs with iPSC-MSCs or BM-MSCs, lymphocyte
proliferation was evaluated using 3H-thymidine (3H-TdR) uptake, carboxyfluo-
rescein diacetate, succinimidyl ester (CFDA-SE) assays; the regulatory T-cell
(Treg) phenotype was determined by flow cytometry, and cytokine levels were
measured using an enzyme-linked immunosorbent assay. The immunomodulatory
properties of both MSCs were further evaluated using NS398 and transwell
experiments.
Results: Similar to BM-MSCs, we determined that iPSC-MSCs significantly inhi-
bit lymphocyte proliferation and promote Treg response in PBMCs (P < 0.05).
Accordingly, the cytokine milieu (IFN-c, IL-4, IL-5, IL-10 and IL-13) in the
supernatants of PBMCs changed significantly (P < 0.05). The immunomodulatory
properties of iPSC-MSCs and BM-MSCs were associated with prostaglandin E2
(PGE2) production and cell–cell contact.
Conclusions: These data demonstrate that iPSC-MSCs are capable of modulating
T-cell phenotypes towards Th2 suppression through inducing Treg expansion,
suggesting that iPSC-MSCs can be used as an alternative candidate to adult
MSCs to treat allergic airway diseases.
Allergic rhinitis (AR) and asthma are characterised by Th2-
skewed eosinophilic inflammation, mucus hypersecretion and
airway hyperresponsiveness (1). The excessive activation of
Th2 cells is thought to play a major role in initiating clinical
features that include allergic sensitisation and driving airway
hyperresponsiveness (2). Over the past few decades, there is
growing evidence that the insufficient suppression of regula-
tory T cells (Treg) is responsible for the excessive Th2
response in allergic airway diseases (3). Therefore, a thera-
peutic strategy that reverses the established Th2 response by
the adoptive transfer of regulatory T cells (Treg) (4–6), toler-
ogenic dendritic cells (DC) (7) and mesenchymal stem cells
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(MSCs) (8–12) may provide a potentially attractive approach
for the management of allergic airway diseases.
Mesenchymal stem cells are ubiquitous multipotent cells
that are abundant in adult bone marrow (BM) and adipose
tissue (13,14). In addition to the potential for tissue repair, a
growing body of evidence has demonstrated that BM-derived
MSCs (BM-MSCs) display profound immunomodulatory
capabilities, making them attractive candidates for the devel-
opment of novel allogeneic cell-based therapeutic strategies in
the treatment of a variety of inflammatory diseases (15–17).
However, it has been reported that adult MSCs (e.g.
BM-MSCs) exhibit several potential weaknesses, such as a
limited proliferative capacity and the rapid loss of differentia-
tion potential, which may affect their therapeutic efficacy
(18–20). A recent breakthrough in the generation of human
induced pluripotent stem cells (iPSCs) from adult somatic
cells using reprogramming techniques (21) offers the possibility
of generating a high yield of MSCs. However, the differentia-
tion potential of human iPSCs into functional MSCs and
their therapeutic efficacy in allergic airway diseases has not
been well documented.
In a previous study, we successfully developed MSCs from
human iPSCs (iPSC-MSCs) that are morphologically and
functionally similar to BM-MSCs (22). Interestingly, we
found that the transplantation of iPSC-MSCs significantly
promotes vascular and muscular regeneration and attenuates
severe hind-limb ischaemia in a mouse model. On the basis
of the observation that iPSC-MSCs exhibit an immunomodu-
latory phenotype, we speculate that iPSC-MSCs may also
function in the prevention of allergic airway diseases. To
address this issue, we compared the immunomodulatory
effects of iPSC-MSCs and BM-MSCs on peripheral blood
mononuclear cells (PBMCs) in patients with AR and evalu-
ated the possible molecular mechanisms underlying the
immunomodulatory properties of these cells.
Materials and methods
Subjects
This study includes 22 patients with persistent allergic rhinitis
(AR) and 34 healthy donors (the details are listed in Table
S1). The diagnosis of persistent AR was in accordance with
the criteria of the initiative from Allergic Rhinitis and its
Impact on Asthma (ARIA) (1). All patients were positive for
Dermatophagoides pteronyssinus (Der p1) (Pharmacia CAP
system, Pharmacia Diagnostics, Uppsala, Sweden). The
patients had not received antihistamines or intranasal steroid
treatments for 1 week, or oral steroids for 3 months, prior to
this study. The Ethics Committee of The First Affiliated
Hospital, Sun Yat-sen University approved this study, and
informed consent was obtained from all participants.
Reagents
Anti-human CD3-PE and isotype-matched control were
purchased from BD Biosciences (San Diego, CA, USA). The
Treg cell kit containing anti-CD4-FITC, CD25-APC and
Foxp3-PE antibodies was purchased from eBioscience (CA,
USA). Enzyme-linked immunosorbent assay (ELISA) kits for
human IFN-c, IL-4, IL-5, IL-10, IL-13, transforming growth
factor-b1 (TGF-b1) and prostaglandin E2 (PGE2) were pur-
chased from R & D (Minneapolis, MN, USA).
Generation of human iPSC-MSCs and identification of
surface markers
Human iPSC-MSCs were prepared as we previously reported
(22). The details are presented in Data S1.
Lymphocyte proliferation assay
The details are presented in Data S1.
Mixed lymphocyte reactions
The details are presented in Data S1.
Flow cytometry analysis
The details are presented in Data S1.
Enzyme-linked immunosorbent assay
The details are presented in Data S1.
Prostaglandin inhibition
The details are presented in Data S1.
Transwell experiments
The details are presented in Data S1.
Statistical analysis
The data are expressed as the mean ± SEM. Statistical
analysis was performed for the Treg cell assay between
groups treated with and without MSCs using the paired Stu-
dent’s t-test. One-way analysis of variance (ANOVA) followed
by post hoc Tukey’s multiple comparisons was used for multi-
ple comparisons between different groups. Comparisons of
two groups were performed using independent sample t tests.
P-values < 0.05 were considered significant.
Results
iPSC-MSCs inhibit phytohaemagglutinin-stimulated PBMC
proliferation
To determine the immunomodulatory properties of iPSC-
MSCs, we examined the effects of iPSC-MSCs on cell
proliferation. As illustrated in Fig. 1, we found that in the
3H-TdR uptake experiment, iPSC-MSCs significantly
inhibited PBMC proliferation at a ratio of 1 : 10 (104 MSCs
vs 105 PBMCs), 1 : 20, 1 : 40, 1 : 80, 1 : 100 and 1 : 1000
(P < 0.05), suggesting iPSC-MSCs inhibited phytohaemagglu-
tinin (PHA)-stimulated lymphocyte proliferation in a dose-
dependent manner. Similarly, BM-MSCs significantly inhibited
PHA-stimulated PBMC proliferation (104 BM-MSCs vs 105
PBMCs). Moreover, we examined the kinetics of the
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immunosuppression of iPSC-MSCs on T-cell proliferation
using multicolour flow cytometric analysis. As illustrated in
Fig. 2, we observed a significant accumulation of T cells in
generation 1 (G1) (parent) and a significant decrease in T-cell
accumulation in G3 and G4 after the addition of iPSC-MSCs
or BM-MSCs (P < 0.05), suggesting that both iPSC-MSCs
and BM-MSCs reduce the number of CD3+ T-cell divisions
and inhibit cell proliferation. In contrast, no significant differ-
ence in the apoptosis of PBMCs, evaluated using annexin V
and propidium iodide labelling, was observed (data not shown).
iPSC-MSCs enhance Treg cell expansion in Der p1-
stimulated PBMCs
To investigate whether iPSC-MSCs modulate Treg cell expan-
sion, we next examined the effects of iPSC-MSCs and BM-
MSCs on Treg frequency in Der p1-stimulated PBMCs using
flow cytometry. As illustrated in Fig. 3, we found no significant
difference in CD4+CD25+ frequency in the CD4+ subpopula-
tion after the treatments of both iPSC-MSCs and BM-MSCs.
However, when we focused on Foxp3+CD4+ Treg cells, we
found that both iPSC-MSCs and BM-MSCs significantly
increased the ratio of Treg cells in the CD4+ subpopulation
(P < 0.05), suggesting iPSC-MSCs exert a tolerogenic effect on
the T-cell response. Interestingly, there was no significant differ-
ence in the Foxp3+CD4+ Treg frequency between the iPSC-
MSCs and BM-MSCs groups.
iPSC-MSCs regulate the cytokine production in Der p1-
stimulated PBMCs
To investigate further the immunomodulatory effects of iPSC-
MSCs on the T-cell phenotype, we next examined the effects
of iPSC-MSCs and BM-MSCs on cytokine production (IFN-
c representing the Th1 phenotype; IL-4, IL-5 and IL-13 repre-
senting the Th2 phenotype; and IL-10 representing the Treg
phenotype) in the supernatants of Der p1-stimulated PBMCs
using ELISA (Fig. 4). The addition of iPSC-MSCs or BM-
MSCs significantly increased IL-10 levels in the iPSC-MSCs
and BM-MSCs groups compared with the control group
(P < 0.01), which was consistent with the increased Treg
frequency observed in stimulated PBMCs. Interestingly, the
IL-10 level in the iPSC-MSCs group was significantly higher
than in the BM-MSCs groups (P < 0.05). On the other hand,
the level of IFN-c was significantly increased and the levels of
IL-4, IL-5, IL-13 were significantly decreased in the iPSC-
MSCs group compared with the control group (P < 0.05).
Similarly, the level of IFN-c was significantly increased and
the level of IL-4 was significantly decreased in the BM-MSCs
group compared with the control group (P < 0.05).
The immunomodulatory properties of iPSC-MSCs are
associated with cell contact and PGE2 production
To parallelly evaluate the molecular mechanisms underlying
the immunomodulatory properties of iPSC-MSCs and BM-
MSCs, we further examined the possible role of cell contact
and PGE2 production in the modulation of Treg frequency
and cytokine levels by MSCs. As illustrated in Fig. 5, both
iPSC-MSCs and BM-MSCs had no significant effect on the
level of TGF-b1 in the supernatants of PHA-stimulated
PBMCs (from healthy volunteers) (Fig. 5A) or Der p1-stimu-
lated PBMCs (from patients with AR) (Fig. 5B). However,
the addition of iPSC-MSCs or BM-MSCs significantly
increased the level of PGE2 in the supernatants of PHA- or
Der p1-stimulated PBMCs, suggesting both types of MSCs
increased PGE2 but not TGF-b1 production in stimulated
PBMCs (P < 0.05). Interestingly, the level of PGE2 decreased
significantly after the addition of NS398, a specific COX-2
inhibitor. Moreover, NS398 significantly reversed the immu-
nomodulatory effect of iPSC-MSCs or BM-MSCs on PHA-
stimulated lymphocyte proliferation, as suggested by the 3H-
TdR uptake assay (Fig. 6A). In addition, similar to NS398,
transwell separation significantly reversed the immunomodu-
latory effect of iPSC-MSCs and BM-MSCs on PHA-stimu-
lated lymphocyte proliferation (Fig. 6B). Moreover, transwell
separation significantly reversed the immunomodulatory
effects of iPSC-MSC and BM-MSCs on the frequency of
Foxp3+CD4+ T cells in the CD4+ subpopulation in Der p1-
stimulated PBMCs (from patients with AR) (Fig. 6C–F).
These findings suggest that both PGE2 and cell contact pre-
vented the iPSC-MSCs and BM-MSCs from exerting immu-
nomodulatory effects on lymphocyte proliferation and the
Treg phenotype.
Discussion
In this study, we took advantage of a short-term, in vitro
culture system to provide preliminary evidence that similar
to BM-MSCs, human iPSC-MSCs exert immunomodula-
tory effects on T-cell phenotypes in PBMCs from patients
with AR. To our knowledge, this is the first study to
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Figure 1 The immunosuppressive effect of iPSC-MSCs on PHA-
stimulated lymphocyte proliferation. iPSC-MSCs significantly
inhibited PHA-stimulated lymphocyte proliferation in a number-
dependent manner, as determined by 3H-TdR uptake. BM-MSCs
were used as a control. PBMCs from healthy volunteers (1 9 105/
well) were stimulated by PHA (5 lg/ml) in a 96-well plate for
3 days in the presence or absence of different numbers of iPSC-
MSCs or BM-MSCs (1 9 104/well) (n = 10). The data are
expressed as the means ± SEM. *P < 0.05; **P < 0.01.
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compare the potential of iPSC-MSCs and BM-MSCs in the
modulation of the allergic response, shedding light on the
clinical use of iPSC-MSCs for the prevention of allergic air-
way diseases.
Over the last decade, MSCs have attracted significant
interest because of their ability to develop into almost
any cell type, which makes them attractive for regenera-
tive medicine. In addition, the importance of MSCs
derived from the BM and adipose tissues in the regula-
tion of allergic airway diseases has been addressed. For
example, Cho et al. reported that adipose tissue-derived
MSCs significantly reduced allergic symptoms and inhib-
ited eosinophilic inflammation in the nasal mucosa in an
ovalbumin-induced AR mouse model (8). Kavanagh et al.
reported that the systemic administration of allogenic
BM-MSCs protected the airways from allergen-induced
pathology by inducing Foxp3+CD4+ Treg cells (11).
More recently, Kapoor et al. demonstrated that BM-
MSCs suppress the proliferation of allergen-challenged
PBMCs from asthmatic subjects through an in vitro stim-
ulation system (12). Although MSCs have not been used
in the clinic, these findings demonstrate the potential
beneficial role of these cells for the management of aller-
gic airway diseases.
In our previous study (22), we successfully isolated three
monoclonal, karyotypically stable and functional iPSC-
MSCs using a combination of CD24 and CD105 sorting.
We demonstrated that these cells did not express pluripo-
tent-associated markers but displayed MSC surface antigens
and differentiated into adipocytes, osteocytes and chondrocytes.
Moreover, transplanting iPSC-MSCs into mice significantly
attenuated severe hind-limb ischaemia, and promoted vascu-
lar and muscle regeneration. Notably, we determined that
the beneficial effects of iPSC-MSCs on limb ischaemia were
superior to those of adult BM-MSCs, suggesting that iPSC-
MSCs are important tools for tissue repair because of their
multipotency properties. However, whether iPSC-MSCs pos-
sess immunosuppressive properties and function in the mod-
ulation of allergic airway diseases is still unclear. To
identify the immunomodulatory properties of iPSC-MSCs,
we first examined the expression of MHC and costimulatory
molecules on iPSC-MSCs in this study. In agreement with
previous reports about iPSC-MSCs (23) and BM-MSCs
(24,25), we found that similar to human BM-MSCs, human
iPSC-MSCs express HLA class I (ABC), low levels of HLA
class II (DR), but not CD80, CD86 or CD40 (data not
shown). This observation suggests the similarity between the
immunosuppressive phenotypes of iPSC-MSCs and BM-
MSCs in vitro. Although iPSCs arising from reprogrammed
adult somatic cells represent an interesting alternative to
embryonic stem cells, the immunosuppressive activity of
iPSC-MSCs has still to be explored and compared with
BM-MSCs. For this reason, we examined further the
immunomodulatory effects of iPSC-MSCs and BM-MSCs
on cell proliferation in PHA-stimulated PBMCs. As
expected, iPSC-MSCs significantly inhibited PHA-stimulated
lymphocyte proliferation in a dose-dependent manner. Using
multicolour flow cytometric analysis, we determined that there
was a significant accumulation of T cells in G1, which was
followed by a significant decrease in T-cell accumulation
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Figure 2 The immunosuppressive effect of iPSC-MSCs on PHA-
stimulated T-cell proliferation. iPSC-MSCs suppressed T-cell prolif-
eration in PHA-stimulated PBMCs, as determined by multicolour
flow cytometric analysis. CFDA-SE-labelled PBMCs from healthy
volunteers (5 9 105 cells/well) were cultured in a 24-well plate for
3 days, and PBMCs were gated for flow cytometric analysis based
on CD3+ staining (A). Representative results of T-cell proliferation
without stimulation (B), PHA (5 lg/ml) stimulation (C), PHA stimula-
tion in the presence of iPSC-MSCs (5 9 104/well) (D) or BM-MSCs
(E) are shown. Both iPSC-MSCs and BM-MSCs significantly
increased the ratio of G1 T cells but decreased the ratio of G3 and
G4 T cells in PHA-stimulated PBMCs (n = 10) (F). The data are
expressed as the means ± SEM. G (generation) indicates the num-
ber of cell divisions. *P < 0.05; **P < 0.01.
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in G3 and G4 after the addition of iPSC-MSCs or BM-
MSCs. Our data suggested that both iPSC-MSCs and BM-
MSCs reduced the number of CD3+ T-cell divisions and
inhibited cell proliferation. Considering that the immuno-
suppressive function of iPS-MSCs is maintained during mul-
tiple passages without any senescence, which is in contrast
Figure 4 Induced pluripotent stem cells-MSCs-modulated cytokine
levels in the supernatants of Der p1-stimulated PBMCs. PBMCs
(1 9 106 cells/well) collected from patients with AR were cultured
in a 24-well plate following Der p1 (10 lg/ml) stimulation in the
presence or absence of iPSC-MSCs or BM-MSCs (5 9 104/well) for
3 days. The levels of IFN-c, IL-4, IL-5, IL-13 and IL-10 in the
supernatants of Der p1-stimulated PBMCs were determined using
ELISA. iPSC-MSCs significantly increased the levels of IFN-c (A)
and IL-10 (B) but decreased the levels of IL-4 (C), IL-5 (D) and IL-13
(E) in the supernatants of Der p1-stimulated PBMCs. For each
group, n = 11. The data are expressed as the means ± SEM.
*P < 0.05; **P < 0.01. nd: no detectable.
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Figure 3 Induced pluripotent stem cells-MSCs enhanced the Treg
frequency in Der p1-stimulated PBMCs, as determined by flow
cytometry. PBMCs from allergic rhinitis (AR) patients (1 9 106
cells/well) were cultured in a 24-well plate following Der p1
(10 lg/ml) stimulation in the presence or absence of iPSC-MSCs
or BM-MSCs (5 9 104/well) for 3 days. Representative flow cyto-
metric results of CD4+CD25+ cells (A) and Foxp3+CD4+ cells (C)
are shown. Both iPSC-MSCs and BM-MSCs significantly increased
the frequency of Foxp3+CD4+ cells (D), but not CD4+CD25+ T
cells (B), in the CD4+ subpopulation after Der p1 stimulation
(n = 5 for each group). The data are expressed as the
means ± SEM. *P < 0.05.
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to BM-MSCs (10 passages vs 3 passages for the BM-
MSCs), it is plausible that compared to BM-MSCs, iPSC-
MSCs may offer a long-lasting, more efficient opportunity
to inhibit cell proliferation in PBMCs.
Mesenchymal stem cells are not globally suppressive and
MSC-mediated immune modulation has generally been
linked to increases in Treg cell numbers and related cyto-
kines (26). However, the immunosuppressive effect of iPSC-
MSCs on the PBMCs from patients with AR is still
unclear. In this study, we compared the effects of iPSC-
MSCs and BM-MSCs on T-cell phenotypes in PBMCs from
patients with AR. As expected, the levels of Th2 cytokines
(IL-4, IL-5, and IL-13) were significantly decreased after
the addition of iPSC-MSCs or BM-MSCs, whereas IL-10
levels were significantly increased. We have consistently
found that both iPSC-MSCs and BM-MSCs significantly
increased the ratio of Treg cells in the CD4+ subpopula-
tion. Interestingly, a significant difference in Foxp3+CD4+
Treg frequency between iPSC-MSCs and BM-MSCs groups
was not observed. Our findings, and those from other
reports, provide evidence that Treg expansion plays a cen-
tral role in the immunomodulatory properties of both
iPSC-MSCs and BM-MSCs.
The mechanisms underlying iPSC-MSCs-mediated Treg
expansion and Th2 suppression in PBMCs are unclear. In
previous studies, apart from the importance of DC modu-
lation (12), the exact mechanisms underlying Treg induc-
tion after the administration of BM-MSCs in allergic
airway diseases have not been identified. It is recognised
that adult MSCs exert immunomodulatory effects on
immune cells through cell–cell contact and soluble inhibi-
tory factors (26). Although the published literature
overwhelmingly demonstrates evidence of Treg-related sup-
pression through the induction of the inhibitory cytokine
TGF-b1 (27), in this study, we did not observe a signifi-
cant change in TGF-b1 levels in the supernatants of cul-
tured PBMCs. However, we observed that iPSC-MSCs
significantly increased PGE2 levels in the supernatants of
PHA- or Derp1-stimulated PBMCs (from healthy controls
or patients with AR, respectively), suggesting that PGE2
might be the cytokine responsible for lymphocyte prolifera-
tion and Treg expansion in PBMCs. This hypothesis was
further substantiated using NS398, a specific COX-2 inhibi-
tor for lymphocyte proliferation. Moreover, transwell sepa-
ration significantly reversed the immunomodulatory effect
of iPSC-MSCs and BM-MSCs on lymphocyte proliferation
as well as Treg induction, providing evidence that cell con-
tact, in addition to cytokine production, was the key mech-
anism utilised by iPSC-MSCs in this short-term, in vitro
culture system.
Figure 5 Induced pluripotent stem cells-MSCs or BM-MSCs modu-
lated the levels of TGF-b1 and PGE2 in the supernatants of PHA or
Der p1-stimulated PBMCs. (A, C) PBMCs from healthy donors
(1 9 105 cells/well) were cultured in a 96-well plate in the presence
of iPSC-MSCs or BM-MSCs (1 9 104 cells/well) for 3 days under
the indicated conditions. (B, D) PBMCs from patients with AR
(1 9 106 cells/well) were cultured in a 24-well plate with 10 lg/ml
Der p1 in the presence of iPSC-MSCs or BM-MSCs (5 9 104 cells/
well) for 3 days. Serum-free medium was used for the TGF-b1
experiments. The levels of TGF-b1 and PGE2 in the supernatants
were determined using ELISA. A significant effect of both iPSC-
MSCs and BM-MSCs on TGF-b1 level was not observed in the su-
pernatants of PHA- or Der p1-stimulated PBMCs (A, B). However,
both iPSC-MSCs and BM-MSCs significantly increased the PGE2
level in the supernatants of PHA- or Derp1-stimulated PBMCs,
which was significantly inhibited by NS398 (C, D). For each group,
n = 6. The data are expressed as the means ± SEM. **P < 0.01.
nd: no detectable.
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Mesenchymal stem cells derived from the BM are used in
most preclinical and clinical studies. But the limited capacity
to proliferate and the quick loss of their differentiation
potential limit their therapeutic efficacy to some extent. iPS-
Cs can generate high yields of MSCs, and patient-specific
iPSC-generated MSCs can be used for autologous transplan-
tation without the need for immunosuppression. This pilot
study parallelly identified the ability of iPSC-MSCs and
BM-MSCs to immunomodulate T-cell phenotypes in cultured
PBMCs from patients with AR. It suggests that iPSC-MSCs
can be used as an alternative candidate to adult MSCs to
treat allergic airway diseases. However, it is noteworthy that
iPSC-MSCs present several challenges. For example, the low
efficiency of iPSC generation and the viral integration of
transgenes cannot be ignored. Moreover, for now, the epige-
netic memory, immune rejection and teratoma formation will
also limit the preclinical and clinical use of cells such as these
(28). Alternatively, the recent development of methodologies
for inducing iPSCs will render iPSC-MSCs an attractive can-
didate for biotherapies.
We acknowledge that this study contains a number of
flaws. For example, the short-term culture system does not
reflect the precise action of iPSC-MSCs, and mechanisms
other than PGE2 production and cell–cell contact cannot be
excluded. Moreover, the validation of the in vitro iPSC-
MSCs data on T-cell modulation cannot be overestimated.
Therefore, it will be of value to perform further in vivo stud-
ies to clarify whether iPSC-MSCs efficiently regulate T cells
and protect against airway inflammation in an AR mouse
model.
In conclusion, we have provided preliminary evidence of
the immunomodulatory properties of iPSC-MSCs and
BM-MSCs for the modulation of T-cell phenotypes in AR.
Because iPSC-MSCs may provide an immeasurable source of
autologous cells that can be prepared from individual
patients, this comparative study has identified iPSC-MSCs as
an attractive candidate for the management of allergic
inflammation in a patient-specific, cost-effective, and batch-
to-batch consistent manner.
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